Idiopathic Pulmonary Fibrosis (IPF) is a chronic lung disease with irreversible fibrosis and poor prognosis. Improved diagnostics are expanding the patient pool, driving demand for more effective treatments. DelveInsight’s report covers 80+ companies developing 100+ IPF drugs, including promising therapies like BMS-986278 and HEC585. Clinical trials are in various stages, with innovative mechanisms of action.
In January 2026, Rein Therapeutics received orphan drug designation from the EMA for LTI-03, aimed at preserving lung function in IPF patients. Agomab Therapeutics reported positive interim results for AGMB-447, an inhaled inhibitor of ALK5 for IPF treatment. GRI Bio, Inc. and Redx Pharma Ltd. also shared positive data from their trials, showing progress in IPF drug development.
DelveInsight’s comprehensive report on IPF pipeline therapies covers key companies like Bristol-Myers Squibb and Roche, offering insights into treatments in different phases of development. The report details promising drugs such as Vixarelimab and TTI-101, with unique mechanisms like STAT3 inhibition and ALK5 inhibition. These therapies aim to address the unmet needs in IPF treatment.
The Idiopathic Pulmonary Fibrosis Pipeline Report by DelveInsight provides a thorough analysis of global pipeline therapies for IPF, categorizing them by clinical stage, route of administration, and mechanism of action. With coverage of key companies and emerging therapies, the report offers valuable insights for stakeholders in the IPF domain, guiding informed decision-making for optimized development strategies.

Read more at GlobeNewswire: Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline